Loading Bonafide Research

South Korea Immunoassays Market Overview, 2031

The South Korea Immunoassays Market is anticipated to grow at more than 6.74% CAGR from 2026 to 2031.

Key Insights


• South Korea has pivoted sharply toward high-sensitivity immunoassay platforms, particularly targeting early-stage neurodegenerative diseases and acute conditions. Local companies have made significant breakthroughs in biomarker detection. For instance, diagnostic companies like JW Bioscience have developed rapid immunoassay platforms to measure specialized blood biomarkers such as WRS (Tryptophanyl-tRNA synthetase) for early sepsis detection, which operates alongside newly approved AI-driven triage software.
• The demand for immunoassay testing in South Korea is heavily accelerated by a historic demographic shift. According to the 2024 Statistics on the Aged, citizens aged 65 and older accounted for 19.2% of the country's population. This figure crossed the 20% mark heading into 2026, shifting South Korea firmly into a super-aged society and drastically escalating the volume of immunoassay-based screenings required for age-related chronic illnesses (such as oncology, endocrinology, and cardiovascular disease markers).
• The market architecture is heavily weighted toward continuous recurring revenue rather than system installations. Consumables, reagents, and kits represent the dominant and fastest-growing slice of the country's immunoassay sector. Because centralized clinical laboratories and medical centers maintain highly automated, closed-ended systems, the ongoing volume of high-throughput testing makes the consumable segment highly inelastic to broader macroeconomic fluctuations.

Market Outlook


• According to the research report, "South Korea Immunoassays Market Outlook, 2031," published by Bonafide Research, the South Korea Immunoassays Market is anticipated to grow at more than 6.74% CAGR from 2026 to 2031.
• South Korea's immunoassay market is expected to witness deep integration with the nation's highly advanced digital health and AI ecosystems. Immunoassay data management software is being bridged directly with Laboratory Information Systems (LIS) and hospital Electronic Health Records (EHR) to facilitate remote diagnostic tracking and decentralized healthcare frameworks.
• While Enzyme-Linked Immunosorbent Assay (ELISA) keeps a large base share, the outlook highlights a clear operational migration toward automated Chemiluminescence Immunoassays (CLIA) and Point-of-Care (POC) multiplexing. Laboratories and localized community clinics are heavily investing in decentralized, portable platforms that can screen multiple infectious or autoimmune targets simultaneously from a single, minute blood or saliva specimen without centralized lab delays.
• Major global and local entities driving the Korean market include Abbott Laboratories, Siemens Healthineers, Sysmex Corporation, Roche Diagnostics, Seegene, and SD Biosensor. Regulatory guidelines, quality control standards, and domestic medical device innovation are structurally supported by prominent organizations such as the Korean In Vitro Diagnostics Association (KIVDA) and the Ministry of Food and Drug Safety (MFDS).

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


Market Dynamics


Driver: Universal NHIS coverage
South Korea’s National Health Insurance Service (NHIS) operates as a single-payer system providing universal healthcare coverage to virtually the entire population. A major driver for the immunoassay market is the government-mandated National Health Screening Program. Under this framework, the NHIS fully subsidizes biannual wellness exams and targeted cancer screenings for citizens over a certain age. This institutional framework locks in massive, predictable testing volumes for core immunoassay panels such as hepatitis antigens, thyroid-stimulating hormones, metabolic biomarkers, and tumor markers (e.g., PSA, CEA) ensuring high laboratory utilization rates across the country
Challenge: Price-volume compressors and reimbursement caps
While the NHIS ensures robust sample volumes, it simultaneously exerts intense pricing pressure on manufacturers. To control national healthcare expenditures, South Korea implements strict reimbursement caps and price-volume agreements. When the clinical volume of a specific immunoassay test surges nationwide, the government frequently scales back the per-test reimbursement rate. This dynamic compresses profit margins for diagnostic laboratories and hospital systems, forcing immunoassay providers to enter into aggressive, low-margin bundled reagent contracts to remain financially viable.
Trend: Rise of companion diagnostics (CDx)
The South Korean diagnostic landscape is undergoing a rapid transition toward precision medicine, explicitly characterized by the integration of immunoassays with targeted oncology therapies. Pharmaceutical and diagnostic companies are increasingly co-developing companion diagnostics specialized immunoassay kits designed to detect specific protein expressions (such as PD-L1 or HER2) to determine if a patient qualifies for advanced immunotherapies. This trend shifts immunoassays away from general screening and turns them into high-value, highly specific treatment-gatekeeping tools.

Policies


• Four-Tier Risk Classification: Immunoassay kits and instruments are categorized from Class I (lowest risk) to Class IV (highest risk, such as blood-screening assays or high-consequence infectious diseases). While Class I requires simple notification, Class II requires third-party certification, and Class III and IV demand comprehensive, direct MFDS technical documentation review and approval.
• The 2026 KGMP Lifecyle Standards: All manufacturers must achieve Korea Good Manufacturing Practice (KGMP) certification. Updated regulatory mandates explicitly dictate that KGMP compliance is no longer assessed independently of market performance. The updated framework links manufacturing quality directly with post-market surveillance (PMS) and real-world clinical performance data.
• Compliance with the Digital Medical Products Act: If an immunoassay system integrates artificial intelligence (AI), machine learning for automated result interpretation, cloud-connectivity, or utilizes standalone software (SaMD), it must comply with this dedicated regulatory pathway. The policy mandates strict validation regarding algorithm transparency, data integrity, and multi-layered cybersecurity protocols.
• Mandatory Quality System Auditor Renewals: Under the revised Medical Device Act, the legal bodies authorized to perform technical documentation reviews and conformity assessments operate on a strict four-year designation validity period. Manufacturers must ensure their designated compliance partners maintain active, renewed status with the MFDS to prevent supply-chain registration delays.

Segment Analysis



Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



South Korea Immunoassays By Technology
• CLIA is the dominant technology in South Korea’s highly automated diagnostics ecosystem, especially across tertiary hospitals in Seoul and Busan. The country’s advanced hospital IT integration (HIS-LIS connectivity) makes CLIA systems highly preferred for real-time reporting and emergency diagnostics. Large university hospitals operate fully automated core labs where CLIA is the default platform for hormone, tumor marker, and infectious disease testing.
• ELISA remains relevant in South Korea primarily in research hospitals, public health institutes, and lower-throughput diagnostic workflows. It is still used in epidemiological surveillance programs and academic biomedical research, but routine clinical testing has largely migrated to automated platforms. ELISA is also important in veterinary diagnostics and academic translational research environments.
• Fluorescence-based immunoassays are widely adopted in South Korea’s emergency and near-patient testing environments. The country’s strong adoption of rapid diagnostics in emergency departments driven by high patient throughput in urban hospitals supports FIA use for cardiac, infectious disease, and respiratory panels.
• RIA has largely been phased out in South Korea’s clinical diagnostics due to strict radiation safety regulation and operational complexity. It is now restricted to niche endocrinology research and legacy hormone assay validation in academic settings. Most clinical hormone testing has fully transitioned to CLIA-based immunoassays.
• ELISpot is primarily used in South Korea’s advanced immunology and vaccine research ecosystem. The country’s strong biotech R&D sector supported by government innovation programs uses ELISpot for T-cell response studies in infectious diseases, cancer immunotherapy research, and vaccine development.
• Western Blot is now largely a confirmatory or research-grade tool in South Korea. It is occasionally used in infectious disease confirmation workflows, but most clinical laboratories have shifted toward automated immunoassay confirmation algorithms to reduce turnaround time and operator dependency.

South Korea Immunoassays By Application
• Infectious disease immunoassays remain highly important in South Korea due to periodic outbreaks and strong national surveillance systems. Testing for hepatitis, tuberculosis screening, influenza, and emerging respiratory viruses is deeply embedded in hospital workflows. The country’s high hospital accessibility ensures rapid diagnostic confirmation using immunoassays.
• Endocrine testing is one of the most routine immunoassay applications in South Korea, driven by high thyroid disorder detection rates and advanced preventive screening culture. Hospitals routinely run hormone panels for thyroid, reproductive health, and metabolic disorders as part of executive health checkups.
• Oncology immunoassays are widely used due to South Korea’s relatively high cancer screening participation rates. Tumor markers such as PSA, CA-125, and AFP are integrated into national screening programs and hospital-based early detection pathways. Cancer screening culture is stronger here than in most APAC countries, supporting sustained immunoassay demand.
• Cardiac biomarker testing is heavily used in South Korea’s emergency departments due to high cardiovascular disease burden in aging populations. Troponin-based immunoassays are a standard tool in chest pain triage protocols in major hospitals.
• Allergy testing is increasingly common due to rising environmental allergens and urban pollution exposure. Immunoassays are used for food allergy panels, respiratory allergens, and atopic disease profiling, particularly in pediatric and dermatology clinics.

South Korea Immunoassays By Product
• Reagents and kits form the most critical recurring revenue stream in South Korea’s immunoassay ecosystem. High automation in hospitals drives continuous reagent consumption, especially in CLIA-based systems. Standardized national health insurance reimbursement supports stable demand for routine diagnostic kits.
• Analyzer demand is concentrated in large hospital laboratories and centralized diagnostic centers. South Korea’s healthcare system favors high-end automated analyzers integrated with robotics and sample tracking systems. Hospitals in metropolitan regions often operate fully consolidated core labs with minimal manual intervention.
• Laboratory informatics systems are highly advanced in South Korea due to its strong digital healthcare infrastructure. Middleware, AI-assisted diagnostics, and hospital-integrated LIS platforms are widely deployed. These systems enable real-time diagnostics, automated reporting, and interoperability with national health databases.

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari


South Korea Immunoassays By End-User
• Hospitals dominate immunoassay usage in South Korea due to the country’s hospital-centric healthcare model. Large tertiary hospitals perform the majority of high-complexity testing, supported by integrated diagnostic laboratories and automated platforms.
• Independent clinical labs exist but are less dominant compared to hospital-based diagnostics. Most high-volume immunoassay testing is centralized within hospital networks, limiting fragmentation and enabling high automation efficiency.
• Blood banks use immunoassays primarily for mandatory infectious disease screening such as hepatitis and HIV. South Korea’s strict blood safety regulations ensure consistent use of standardized immunoassay protocols.
• Others include government health agencies, academic research institutes, and national disease surveillance programs. South Korea’s strong public health infrastructure supports continuous immunoassay use for epidemiology, vaccine monitoring, and outbreak preparedness.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Immunoassays Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Chemiluminescence Immunoassays (CLIA)
• Enzyme Immunoassays (ELISA/EIA)
• Fluorescence Immunoassays (FIA/IFA/ELFA)
• Radioimmunoassays (RIA)
• Rapid/Lateral Flow Immunoassays
• ELISpot
• Western Blot
• Multiplex & Other Immunoassays

By Application
• Infectious Disease Testing
• Endocrinology Testing
• Oncology Testing
• Cardiology Testing
• Autoimmune Disease Testing
• Therapeutic Drug Monitoring
• Allergy Diagnostics
• Other Applications

By Product
• Reagents & Kits
• Analyzers & Instruments
• Software & Services

By End User
• Hospitals & Clinics
• Clinical Laboratories
• Blood Banks
• Pharmaceutical & Biotechnology Companies
• Others

Table of Contents

  • 1. Executive Summary
  • 2. Market Structure
  • 2.1. Market Considerate
  • 2.2. Assumptions
  • 2.3. Limitations
  • 2.4. Abbreviations
  • 2.5. Sources
  • 2.6. Definitions
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. South Korea Geography
  • 4.1. Population Distribution Table
  • 4.2. South Korea Macro Economic Indicators
  • 5. Market Dynamics
  • 5.1. Key Insights
  • 5.2. Recent Developments
  • 5.3. Market Drivers & Opportunities
  • 5.4. Market Restraints & Challenges
  • 5.5. Market Trends
  • 5.6. Supply chain Analysis
  • 5.7. Policy & Regulatory Framework
  • 5.8. Industry Experts Views
  • 6. South Korea Immunoassays Market Overview
  • 6.1. Market Size By Value
  • 6.2. Market Size and Forecast, By Technology
  • 6.3. Market Size and Forecast, By Application
  • 6.4. Market Size and Forecast, By Product
  • 6.5. Market Size and Forecast, By End User
  • 6.6. Market Size and Forecast, By Region
  • 7. South Korea Immunoassays Market Segmentations
  • 7.1. South Korea Immunoassays Market, By Technology
  • 7.1.1. South Korea Immunoassays Market Size, By Chemiluminescence Immunoassays (CLIA), 2020-2031
  • 7.1.2. South Korea Immunoassays Market Size, By Enzyme Immunoassays (ELISA/EIA), 2020-2031
  • 7.1.3. South Korea Immunoassays Market Size, By Fluorescence Immunoassays (FIA/IFA/ELFA), 2020-2031
  • 7.1.4. South Korea Immunoassays Market Size, By Radioimmunoassays (RIA), 2020-2031
  • 7.1.5. South Korea Immunoassays Market Size, By Rapid/Lateral Flow Immunoassays, 2020-2031
  • 7.1.6. South Korea Immunoassays Market Size, By ELISpot, 2020-2031
  • 7.1.7. South Korea Immunoassays Market Size, By Western Blot, 2020-2031
  • 7.1.8. South Korea Immunoassays Market Size, By Multiplex & Other Immunoassays, 2020-2031
  • 7.2. South Korea Immunoassays Market, By Application
  • 7.2.1. South Korea Immunoassays Market Size, By Infectious Disease Testing, 2020-2031
  • 7.2.2. South Korea Immunoassays Market Size, By Endocrinology Testing, 2020-2031
  • 7.2.3. South Korea Immunoassays Market Size, By Oncology Testing, 2020-2031
  • 7.2.4. South Korea Immunoassays Market Size, By Cardiology Testing, 2020-2031
  • 7.2.5. South Korea Immunoassays Market Size, By Autoimmune Disease Testing, 2020-2031
  • 7.2.6. South Korea Immunoassays Market Size, By Therapeutic Drug Monitoring, 2020-2031
  • 7.2.7. South Korea Immunoassays Market Size, By Allergy Diagnostics, 2020-2031
  • 7.2.8. South Korea Immunoassays Market Size, By Other Applications, 2020-2031
  • 7.3. South Korea Immunoassays Market, By Product
  • 7.3.1. South Korea Immunoassays Market Size, By Reagents & Kits, 2020-2031
  • 7.3.2. South Korea Immunoassays Market Size, By Analyzers & Instruments, 2020-2031
  • 7.3.3. South Korea Immunoassays Market Size, By Software & Services, 2020-2031
  • 7.4. South Korea Immunoassays Market, By End User
  • 7.4.1. South Korea Immunoassays Market Size, By Hospitals & Clinics, 2020-2031
  • 7.4.2. South Korea Immunoassays Market Size, By Clinical Laboratories, 2020-2031
  • 7.4.3. South Korea Immunoassays Market Size, By Blood Banks, 2020-2031
  • 7.4.4. South Korea Immunoassays Market Size, By Pharmaceutical & Biotechnology Companies, 2020-2031
  • 7.4.5. South Korea Immunoassays Market Size, By Others, 2020-2031
  • 7.5. South Korea Immunoassays Market, By Region
  • 7.5.1. South Korea Immunoassays Market Size, By North, 2020-2031
  • 7.5.2. South Korea Immunoassays Market Size, By East, 2020-2031
  • 7.5.3. South Korea Immunoassays Market Size, By West, 2020-2031
  • 7.5.4. South Korea Immunoassays Market Size, By South, 2020-2031
  • 8. South Korea Immunoassays Market Opportunity Assessment
  • 8.1. By Technology, 2026 to 2031
  • 8.2. By Application, 2026 to 2031
  • 8.3. By Product, 2026 to 2031
  • 8.4. By End User, 2026 to 2031
  • 8.5. By Region, 2026 to 2031
  • 9. Competitive Landscape
  • 9.1. Porter's Five Forces
  • 9.2. Company Profile
  • 9.2.1. Company 1
  • 9.2.1.1. Company Snapshot
  • 9.2.1.2. Company Overview
  • 9.2.1.3. Financial Highlights
  • 9.2.1.4. Geographic Insights
  • 9.2.1.5. Business Segment & Performance
  • 9.2.1.6. Product Portfolio
  • 9.2.1.7. Key Executives
  • 9.2.1.8. Strategic Moves & Developments
  • 9.2.2. Company 2
  • 9.2.3. Company 3
  • 9.2.4. Company 4
  • 9.2.5. Company 5
  • 9.2.6. Company 6
  • 9.2.7. Company 7
  • 9.2.8. Company 8
  • 10. Strategic Recommendations
  • 11. Disclaimer

Table 1: Influencing Factors for Immunoassays Market, 2025
Table 2: South Korea Immunoassays Market Size and Forecast, By Technology (2020 to 2031F) (In USD Million)
Table 3: South Korea Immunoassays Market Size and Forecast, By Application (2020 to 2031F) (In USD Million)
Table 4: South Korea Immunoassays Market Size and Forecast, By Product (2020 to 2031F) (In USD Million)
Table 5: South Korea Immunoassays Market Size and Forecast, By End User (2020 to 2031F) (In USD Million)
Table 6: South Korea Immunoassays Market Size and Forecast, By Region (2020 to 2031F) (In USD Million)
Table 7: South Korea Immunoassays Market Size of Chemiluminescence Immunoassays (CLIA) (2020 to 2031) in USD Million
Table 8: South Korea Immunoassays Market Size of Enzyme Immunoassays (ELISA/EIA) (2020 to 2031) in USD Million
Table 9: South Korea Immunoassays Market Size of Fluorescence Immunoassays (FIA/IFA/ELFA) (2020 to 2031) in USD Million
Table 10: South Korea Immunoassays Market Size of Radioimmunoassays (RIA) (2020 to 2031) in USD Million
Table 11: South Korea Immunoassays Market Size of Rapid/Lateral Flow Immunoassays (2020 to 2031) in USD Million
Table 12: South Korea Immunoassays Market Size of ELISpot (2020 to 2031) in USD Million
Table 13: South Korea Immunoassays Market Size of Western Blot (2020 to 2031) in USD Million
Table 14: South Korea Immunoassays Market Size of Multiplex & Other Immunoassays (2020 to 2031) in USD Million
Table 15: South Korea Immunoassays Market Size of Infectious Disease Testing (2020 to 2031) in USD Million
Table 16: South Korea Immunoassays Market Size of Endocrinology Testing (2020 to 2031) in USD Million
Table 17: South Korea Immunoassays Market Size of Oncology Testing (2020 to 2031) in USD Million
Table 18: South Korea Immunoassays Market Size of Cardiology Testing (2020 to 2031) in USD Million
Table 19: South Korea Immunoassays Market Size of Autoimmune Disease Testing (2020 to 2031) in USD Million
Table 20: South Korea Immunoassays Market Size of Therapeutic Drug Monitoring (2020 to 2031) in USD Million
Table 21: South Korea Immunoassays Market Size of Allergy Diagnostics (2020 to 2031) in USD Million
Table 22: South Korea Immunoassays Market Size of Other Applications (2020 to 2031) in USD Million
Table 23: South Korea Immunoassays Market Size of Reagents & Kits (2020 to 2031) in USD Million
Table 24: South Korea Immunoassays Market Size of Analyzers & Instruments (2020 to 2031) in USD Million
Table 25: South Korea Immunoassays Market Size of Software & Services (2020 to 2031) in USD Million
Table 26: South Korea Immunoassays Market Size of Hospitals & Clinics (2020 to 2031) in USD Million
Table 27: South Korea Immunoassays Market Size of Clinical Laboratories (2020 to 2031) in USD Million
Table 28: South Korea Immunoassays Market Size of Blood Banks (2020 to 2031) in USD Million
Table 29: South Korea Immunoassays Market Size of Pharmaceutical & Biotechnology Companies (2020 to 2031) in USD Million
Table 30: South Korea Immunoassays Market Size of Others (2020 to 2031) in USD Million
Table 31: South Korea Immunoassays Market Size of North (2020 to 2031) in USD Million
Table 32: South Korea Immunoassays Market Size of East (2020 to 2031) in USD Million
Table 33: South Korea Immunoassays Market Size of West (2020 to 2031) in USD Million
Table 34: South Korea Immunoassays Market Size of South (2020 to 2031) in USD Million

Figure 1: South Korea Immunoassays Market Size By Value (2020, 2025 & 2031F) (in USD Million)
Figure 2: Market Attractiveness Index, By Technology
Figure 3: Market Attractiveness Index, By Application
Figure 4: Market Attractiveness Index, By Product
Figure 5: Market Attractiveness Index, By End User
Figure 6: Market Attractiveness Index, By Region
Figure 7: Porter's Five Forces of South Korea Immunoassays Market

South Korea Immunoassay Market Research FAQs

Growing disease screening programs, expanding laboratory infrastructure, and increasing adoption of biomarker-based diagnostics are driving demand.

They offer standardized, reliable, and cost-effective testing for a broad range of clinical and research applications.

Hospitals, diagnostic laboratories, and specialty clinics are the leading users due to high routine testing volumes.

They are consumable products required for every test, ensuring continuous laboratory operations and consistent assay performance.
Logo

South Korea Immunoassays Market Overview, 2031

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Claude Summarize

Contact usWe are friendly and approachable, give us a call.